|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.600 USD | -1.13% |
|
-.--% | - |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index | CI |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index | CI |
| Market Cap | 97.22M 84.2M 78.49M 72.19M 136M 9.24B 138M 922M 362M 4.63B 365M 357M 15.32B | P/E 2023 |
-4.07x | P/E 2024 | -3.15x |
|---|---|---|---|---|---|
| Enterprise Value | 142M 123M 114M 105M 199M 13.47B 201M 1.34B 528M 6.74B 532M 520M 22.33B | EV / Sales 2023 |
2.86x | EV / Sales 2024 | 1.43x |
| Free-Float |
6.21% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -1.13% |
| 3 years | 4.81 |  | 31.5 |
| 5 years | 4.81 | | 64.5 |
| 10 years | 4.81 | | 450 |
| Manager | Title | Age | Since |
|---|---|---|---|
Evan Loh
CEO | Chief Executive Officer | 67 | 2025-05-20 |
| Chief Tech/Sci/R&D Officer | - | 2019-12-31 | |
Jonathan Neely
IRC | Investor Relations Contact | - | 2020-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Evan Loh
BRD | Director/Board Member | 67 | 2025-05-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/21/25 | Issuer sale | Chief Financial Officer | 82,491 | 0.8204% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -.--% | -.--% | -49.61% | 97.22M | |
| +4.00% | -4.21% | +51.32% | +155.26% | 995B | |
| +1.46% | -2.67% | +51.36% | +49.30% | 614B | |
| +0.78% | -6.65% | +23.80% | +63.51% | 431B | |
| +1.96% | +0.83% | +42.80% | +37.70% | 353B | |
| -0.11% | -4.07% | +30.37% | +38.52% | 293B | |
| +2.52% | -8.36% | +7.27% | +10.56% | 245B | |
| +3.50% | +4.23% | +34.64% | +59.73% | 210B | |
| -4.32% | -12.94% | -3.79% | -46.07% | 210B | |
| -2.82% | -0.41% | +17.54% | +63.87% | 168B | |
| Average | +0.68% | -4.52% | +25.53% | +38.28% | 351.83B | |
| Weighted average by Cap. | +1.79% | -5.89% | +36.40% | +71.88% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 70.99M 61.48M 57.31M 52.71M 99.51M 6.75B 101M 673M 264M 3.38B 267M 261M 11.19B | 78.23M 67.75M 63.16M 58.09M 110M 7.44B 111M 742M 291M 3.72B 294M 287M 12.33B |
| Net income | -35.48M -30.73M -28.65M -26.35M -49.74M -3.37B -50.3M -337M -132M -1.69B -133M -130M -5.59B | -21.54M -18.66M -17.39M -16M -30.2M -2.05B -30.53M -204M -80.21M -1.02B -80.9M -79.12M -3.39B |
| Net Debt | 58.06M 50.29M 46.88M 43.12M 81.4M 5.52B 82.31M 551M 216M 2.76B 218M 213M 9.15B | 44.48M 38.52M 35.91M 33.03M 62.35M 4.23B 63.04M 422M 166M 2.12B 167M 163M 7.01B |
Employees
128
Sector
Pharmaceuticals
- Stock Market
- Stocks
- OPTN Stock
Select your edition
All financial news and data tailored to specific country editions
